Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.
The emergence of clinical enterococcal isolates resistant to both ampicillin and vancomycin is a cause of great concern, as there are few therapeutic alternatives for treatment of infections caused by such organisms. We evaluated the effects of the combination of ampicillin with vancomycin against vancomycin-resistant clinical enterococcal isolates. Using both the checkerboard technique and time-kill curves, we examined 28 strains of enterococci (17 Enterococcus faecalis and 11 Enterococcus faecium strains) with different levels of resistance to vancomycin. Of these, 15 strains were also highly gentamicin resistant, and 9 demonstrated resistance to ampicillin. Only seven strains of E. faecalis were inhibited synergistically by the combination of vancomycin with ampicillin, and even then, the concentrations of vancomycin at which synergism was demonstrated were above levels achievable in serum. None of the ampicillin-resistant isolates (all E. faecium) were inhibited synergistically at any concentration of the drugs. In no instance was bactericidal synergism observed, and in most cases the combination resulted in less killing than with ampicillin alone. Antagonism was not observed at clinically relevant concentrations. The results of this study suggest that the combination of vancomycin with ampicillin has little to offer against these emerging pathogens.
Cercenado
E
E
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts.
Eliopoulos
G M
GM
Wennersten
C B
CB
Moellering
R C
RC
D000667:Ampicillin / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D016983:Enterococcus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000494:pharmacology*
D014640:Vancomycin; D000667:Ampicillin